Home › Research › Down syndrome and Alzheimer's
Myoclonic epilepsy in Down syndrome and Alzheimer disease
Aller-Alvarez JS, Menéndez-González M, Ribacoba-Montero R, Salvado M, Vega V, Suárez-Moro R, Sueiras M, Toledo M et al.. Neurologia (Barcelona, Spain), 2015-02-07
Topic: Brain proteins, microglia and lab models
Plain-language summary
Introduction Patients with Down syndrome (DS) who exhibit Alzheimer disease (AD) are associated with age. Both diseases with a common neuropathological basis have been associated with late-onset myoclonic epilepsy (LOMEDS). This entity presents electroencephalogram features as generalized polyspike-wave discharges. Method We present a series of 11 patients with the diagnosis of DS or AD who developed myoclonic seizures or generalized tonic-clonic seizures. In all cases, clinical and neuroimaging studies and polygraph EEG monitoring was performed. Results In all cases, cognitive impairment progressed quickly after the onset of epilepsy causing an increase in the degree of dependence. The most common finding in the EEG was a slowing of brain activity with theta and delta rhythms, plus intercritical generalized polyspike-waves were objectified in eight patients. In neuroimaging studies was found cerebral cortical atrophy. The most effective drug in this series was the levetiracetam. Conclusions The association of generalized epilepsy with elderly DS represents an epiphenomenon in evolution which is associated with a progressive deterioration of cognitive and motor functions. This epilepsy has some electroclinical characteristics and behaves as progressive myoclonic epilepsy, which is probably related to the structural changes that characterize the evolutionary similarity of DS with AD. Recognition of this syndrome is important, since it has prognostic implications and requires proper treatment.
What this study adds
Evidence grade: Low
This case series of 11 patients with Down syndrome or Alzheimer's disease describes myoclonic epilepsy that appeared with age and was followed by faster cognitive decline. Levetiracetam was the most effective drug in this series, but this is a small observational report and does not show that treating seizures prevents or cures Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Aller-Alvarez, J. S., Menéndez-González, M., Ribacoba-Montero, R., Salvado, M., Vega, V., Suárez-Moro, R., et al. (2017). Myoclonic epilepsy in Down syndrome and Alzheimer disease. Neurologia (Barcelona, Spain). https://doi.org/10.1016/j.nrl.2014.12.008
Vancouver
Aller-Alvarez JS, Menéndez-González M, Ribacoba-Montero R, Salvado M, Vega V, Suárez-Moro R, et al. Myoclonic epilepsy in Down syndrome and Alzheimer disease. Neurologia (Barcelona, Spain). 2017. doi:10.1016/j.nrl.2014.12.008. PMID: 25661268.
BibTeX
@article{alleralvarez2017-25661268,
author = {Aller-Alvarez, J. S. and Menéndez-González, M. and Ribacoba-Montero, R. and Salvado, M. and Vega, V. and Suárez-Moro, R. and Sueiras, M. and Toledo, M. and others},
title = {{Myoclonic epilepsy in Down syndrome and Alzheimer disease}},
journal = {Neurologia (Barcelona, Spain)},
year = {2017},
doi = {10.1016/j.nrl.2014.12.008},
pmid = {25661268},
url = {https://doi.org/10.1016/j.nrl.2014.12.008}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Introduction Patients with Down syndrome (DS) who exhibit Alzheimer disease (AD) are associated with age.
- Both diseases with a common neuropathological basis have been associated with late-onset myoclonic epilepsy (LOMEDS).
- Results In all cases, cognitive impairment progressed quickly after the onset of epilepsy causing an increase in the degree of dependence.
- Conclusions The association of generalized epilepsy with elderly DS represents an epiphenomenon in evolution which is associated with a progressive deterioration of cognitive and motor functions.
Why it matters
This case series of 11 patients with Down syndrome or Alzheimer's disease describes myoclonic epilepsy that appeared with age and was followed by faster cognitive decline. Levetiracetam was the most effective drug in this series, but this is a small observational report and does not show that treating seizures prevents or cures Alzheimer's disease.
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record and multicenter collaboration, so those were left out: it earned 23 of the 64 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurologia (Barcelona, Spain)) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2017 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (OpenAlex dates this DOI to 2015, the record says 2017; OpenAlex values not used) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 25661268) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 64 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 23 of the 64 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Down syndrome and Alzheimer's from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.